The guidance used an economic model which NICE was given in confidence, and more effort should have been made to make it available for public scrutiny, Mr Justice Holman said.
The ruling has been welcomed by the National Osteoporosis Society. It said the decision would provide the opportunity to prove the economic model NICE used was flawed. The charity says this is 'key to securing cost-effective treatments for a wide range of people'.
Servier Laboratories challenged NICE at judicial review because it believed the guidance unfairly restricted access to its drug Protelos (strontium ranelate).
Comment below and tell us what you think